Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2012

View Archived Issues

TOCA therapy increases survival in models of brain cancer

Sanofi prepares novel fibroblast growth factor receptor antagonists

Zalicus and Hydra Biosciences to collaborate on ion channel modulators

Washington University study reveals mechanisms behind AML relapse

Phase IIb data on iferanserin support ongoing phase III study

Algeta reports updated data from phase III ALSYMPCA trial

FDA warns of drug interactions with Victrelis

FDA warns for increased risk of CDI-associated diarrhea with proton pump inhibitor use

Pergamum completes recruitment in PXL-01 study

Zealand Pharma to receive milestone payment following completion of GetGoal program

FDA issues draft guidance to assist industry in developing biosimilar products

Dainippon Sumitomo Pharma updates progress of third quarter of fiscal 2011

Santarus commences study of Uceris added to 5-ASA therapy

Advinus Therapeutics and Celgene Global Health enter collaboration

Large phase II trial assesses meningococcal vaccine in infants

Pfizer launches Inlyta in U.S.

Insmed to proceed with clinical studies of Arikace in U.S. and Europe

Kaken Pharmaceutical patents new ADAM inhibitors

U.S. university designs new siRNA products for Sjogren's syndrome

Dicerna Pharmaceuticals patents new RNA-based products

New anticancer products developed

Zhe-Jiang Beta Pharma presents novel PARP-1 inhibitors

Bayer reports novel candidate cancer therapeutics

Novartis receives response from FDA regarding Menveo sBLA

UCB Pharma enters collaboration with Nodality

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Aug. 3, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...